

(FILE 'HOME' ENTERED AT 08:49:45 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:49:58 ON 14 MAR 2007

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 50 S L2
L4 34165 S L3 SSS FULL
L5 0 S L1 SUB=L4 FULL
L6 STRUCTURE UPLOADED
L7 33945 S L6 SUB=L4 FULL
L8 220 S L4 NOT L7

FILE 'CAPLUS' ENTERED AT 08:53:37 ON 14 MAR 2007

L9 15 S L8/THU
L10 8 S L9 AND (INTERFERON OR (TOLL-LIKE) OR CANCER OR VIRUS OR VIRAL
L11 0 S L10 AND (INTERFERON OR (TOLL-LIKE))
L12 183 S L8
L13 0 S L12 AND (INTERFERON OR (TOLL-LIKE))
L14 10 S L12 AND (OLIGONUCLEOTIE OR POLYNUCLEOTIDE)
L15 49 S L12 AND (OLIGONUCLEOTIDE OR POLYNUCLEOTIDE)
L16 4 S L15 AND (CANCER OR TUMOR OR NEOPLAS?)

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:49:58 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6
DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10824833nucnot.str



chain nodes :

7 8 20 21 22 23 24 25 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 9 10 11 14 15 16 17 18

chain bonds :

2-8 4-7 10-31 11-14 14-29 16-22 16-26 17-21 17-27 18-20 18-28 22-23
22-24

22-25 23-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 6-11 9-10 10-11 14-15 14-18 15-16 16-17
17-18

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 5-9 6-11 9-10 10-11 10-31 14-15 14-18
15-16 16-17 17-18 17-21 18-20 22-23 23-30

exact bonds :

11-14 14-29 16-22 16-26 17-27 18-28 22-24 22-25

G1:C,S,N

G2:C,N

G3:H,O

G4:H,Cl,Br,F,I,NO2



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10824833nuc2.str



chain nodes :

7 8 20 21 22 23 24 25 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 9 10 11 14 15 16 17 18

chain bonds :

2-8 4-7 10-31 11-14 14-29 16-22 16-26 17-21 17-27 18-20 18-28 22-23

22-24

22-25 23-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 6-11 9-10 10-11 14-15 14-18 15-16 16-17

17-18

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 5-9 6-11 9-10 10-11 10-31 11-14 14-15

14-18 14-29 15-16 16-17 16-22 16-26 17-18 17-21 17-27 18-20 18-28 22-23

22-24 22-25

23-30

G1:C,S,N

G2:C,N

G3:H,O

G4:H,Cl,Br,F,I,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

L2 STRUCTURE UPLOADED

=> d l2

L2 HAS NO ANSWERS

L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l2

SAMPLE SEARCH INITIATED 08:50:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1985 TO ITERATE

100.0% PROCESSED 1985 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 37028 TO 42372

PROJECTED ANSWERS: 31103 TO 36017

L3 50 SEA SSS SAM L2

=> s l3 sss full

FULL SEARCH INITIATED 08:50:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 40417 TO ITERATE

100.0% PROCESSED 40417 ITERATIONS

34165 ANSWERS

SEARCH TIME: 00.00.01

L4 34165 SEA SSS FUL L2

=> s L1 sub=L4

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 08:51:18 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS

0 ANSWERS


SEARCH TIME: 00.00.01

L5 0 SEA SUB=L4 SSS FUL L1


=> d 14 scan

```
L4 34165 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C52 H57 B F2 N9 O18 P3 S
CI CCS, COM
```

PAGE 1-A



PAGE 1-B




PAGE 1-C

$$-\text{NH}_2$$
$$-\text{CH}=\text{CH}_2$$


HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3

PAGE 1-A



● 2 H⁺

PAGE 1-B



—NH₂


—CH=CH₂

L4 34165 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C78 H99 N30 O46 P7 . 1/2 C16 H12 N2 O4



CM 1

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A








CM 2




L4 34165 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C57 H70 N21 O42 P5


Absolute stereochemistry.



PAGE 2-A





PAGE 2-B



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10823844nucnot2.str



chain nodes :

7 8 20 21 22 23 24 25 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 9 10 11 14 15 16 17 18

chain bonds :

2-8 4-7 10-31 11-14 14-29 16-22 16-26 17-21 17-27 18-20 18-28 22-23

22-24

22-25 23-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 6-11 9-10 10-11 14-15 14-18 15-16 16-17

17-18

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 5-9 6-11 9-10 10-11 10-31 11-14 14-15

14-18 15-16 16-17 17-18 17-21 18-20 22-23 23-30

exact bonds :

14-29 16-22 16-26 17-27 18-28 22-24 22-25

G1:C,S,N

G2:C,N

G3:H,O

G4:H,Cl,Br,F,I,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

L6 STRUCTURE UPLOADED

=> s L6 sub=L4

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 08:52:45 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 33951 TO ITERATE

100.0% PROCESSED 33951 ITERATIONS

33945 ANSWERS

SEARCH TIME: 00.00.01

L7 33945 SEA SUB=L4 SSS FUL L6

=> s l4 not L7

L8 220 L4 NOT L7


=> d l8 scan

L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-
[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-
ribofuranosyl]-1,7-dihydro- (9CI)

MF C11 H16 F N4 O13 P3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4


L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN



IN 7-Deazaguanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxy-7-deazaguananylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-7-deazaguananylyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-2'-deoxy-(9CI)

MF C60 H76 N21 O34 P5

Absolute stereochemistry.

PAGE 1-A











PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 7-Deazaguanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxy-7-
 deazaguanilyl-(3'→5')-2'-deoxyadenilyl-(3'→5')-2'-
 deoxyadenilyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-
 (3'→5')-2'-deoxy- (9CI)
 MF C70 H88 N26 O39 P6

Absolute stereochemistry.






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Borate(4-), [N-[3-[2-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphiny
 l]oxy]phosphinyl]-β-D-ribofuranosyl]-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-
 d]pyrimidin-5-yl]-2-propynyl]-5-[[5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene-
 κN]methyl]-1H-pyrrole-2-propanamido(5-)-κN1]difluoro-,
 tetrahydrogen, (T-4)- (9CI)
 MF C30 H28 B F2 N8 O15 P3 . 4 H
 CI CCS

PAGE 1-A




● 4 H⁺

PAGE 1-B



L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Acetamide, N-[3-[2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)
)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo-1H-pyrrolo[2,3-
 d]pyrimidin-5-yl]-2-propynyl]-2,2,2-trifluoro- (9CI)
 MF C16 H19 F3 N5 O15 P3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):file caplus
'FILE CAPLUS' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
255.65	255.86

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:53:37 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 18/thu
183 L8
866657 THU/RL
L9 15 L8/THU
(L8 (L) THU/RL)

=> s 19 and (interferon or (toll-like) or cancer or virus or viral)
75756 INTERFERON

8174 TOLL
 779783 LIKE
 7160 TOLL-LIKE
 (TOLL(W) LIKE)
 308734 CANCER
 357456 VIRUS
 167790 VIRAL

L10 8 L9 AND (INTERFERON OR (TOLL-LIKE) OR CANCER OR VIRUS OR VIRAL)

=> d l10 1-8 hitstr


L10 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 98259-20-2 101515-08-6 181356-39-8
 213623-48-4 244109-12-4 377048-29-8
 444019-41-4 444019-42-5 444019-43-6
 444019-46-9 444019-47-0 444019-48-1
 444019-50-5 444019-52-7 444019-53-8
 444019-79-8 444021-39-0 847649-04-1
 847649-60-9 847650-14-0 847650-15-1
 847650-28-6 847650-29-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (comps. and methods for treatment of severe acute respiratory
 syndrome)

RN 98259-20-2 CAPLUS


CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[5-O-
 [hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-
 ribofuranosyl]- (9CI) (CA INDEX NAME)



RN 101515-08-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-
 [hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-
 pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 181356-39-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-

[hydroxy [(hydroxy (phosphonoxy) phosphinyl) oxy] phosphinyl] - β -D-ribofuranosyl] - (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213623-48-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[(hydroxy [(hydroxy (phosphonoxy) phosphinyl) oxy] phosphinyl] - β -D-erythro-pentofuranosyl]-5-ethyl-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244109-12-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[(hydroxy [(hydroxy (phosphonoxy) phosphinyl) oxy] phosphinyl] - β -D-erythro-pentofuranosyl]-1,7-dihydro-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 377048-29-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[(hydroxy [(hydroxy (phosphonoxy) phosphinyl) oxy] phosphinyl] - β -D-erythro-

pentofuranosyl]-1,7-dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-41-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[(hydroxy[(hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl)]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-42-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[(hydroxy[(hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl)]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444019-43-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-ethyl-1,7-dihydro-7-[5-O-[(hydroxy[(hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl)]-β-D-

ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-46-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-47-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-48-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-50-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-52-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-53-8 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-79-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-
[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-
ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-39-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-
[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-
arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847649-04-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-
[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-α-D-
arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847649-60-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-beta-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-14-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-D-arabinofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-15-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-alpha-D-arabinofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-28-6 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-3,5-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-29-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[bis[2-[(trifluoroacetyl)thio]ethoxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 444019-45-8 444021-39-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(a 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic

properties)

RN 444019-45-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-39-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN



IT 499212-95-2



RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (immunomodulatory oligonucleotide compns. for use with microcarriers)

RN 499212-95-2 CAPLUS


CN Thymidine, P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thio-7-deazaguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





PAGE 2-A



PAGE 2-B

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 101515-08-6P 181356-39-8P 444019-15-2P

444019-41-4P 444019-42-5P 444019-43-6P

444019-45-8P 444019-46-9P 444019-47-0P

444019-48-1P 444019-49-2P 444019-50-5P

444019-51-6P 444019-52-7P 444019-53-8P

444019-79-8P 444020-98-8P 444021-00-5P

444021-01-6P 444021-06-1P 444021-07-2P

444021-10-7P 444021-11-8P 444021-12-9P

444021-36-7P 444021-37-8P 444021-39-0P

444021-40-3P 444021-41-4P 444021-42-5P

444021-69-6P 444021-77-6P 444021-80-1P

444021-81-2P 444021-84-5P 444021-85-6P


RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

RN 101515-08-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 181356-39-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-15-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[bis[2-[(2,2-dimethyl-1-oxopropyl)thio]ethoxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-41-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-42-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-43-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-ethyl-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-45-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-46-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-47-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-48-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-49-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-1,7-dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-50-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-51-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444019-52-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-5-O-

[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-erythro-pentofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-53-8 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-79-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444020-98-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-

trioxa-1-phosphaoct-1-yl]- β -D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-00-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]- β -D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-01-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-ethyl-1,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-06-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-O-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-07-2 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[2-O-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-10-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444021-11-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[2-O-

methyl-5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]-4-oxo- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 444021-12-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-[2-O-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-36-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-37-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]-1,7-dihydro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 444021-39-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-40-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-41-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-42-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-69-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-erythro-pentofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-77-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-80-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-81-2 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-iodo-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444021-84-5 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444021-85-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 101515-08-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);


USES (Uses)

(controlling the fidelity and the process-execution of reverse transcriptase by incorporating and polymerizing nucleotide analogs acceptable as substrates for reverse transcription without blocking elongation)

RN 101515-08-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 252722-18-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(nucleotide analogs for modulation and inhibition of telomerase for treatment of cancer)

RN 252722-18-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[(hydroxy[(hydroxy(phosphonooxy)phosphinyl]oxy)phosphinyl]]-β-D-erythro-pentofuranosyl]-3,7-dihydro-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 101515-08-6


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nucleotide analogs for modulation and inhibition of telomerase for treatment of cancer)

RN 101515-08-6 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[(hydroxy[(hydroxy(phosphonooxy)phosphinyl]oxy)phosphinyl]]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 101515-08-6, 7-Deaza-2'-deoxyguanosine 5'-triphosphate
 104904-92-9 187478-95-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nucleotide and nucleoside analogs for modulation and inhibition of telomerase, analog preparation, and use for cancer treatment)
 RN 101515-08-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 104904-92-9 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy(phosphonooxy)phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187478-95-1 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonomethyl)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 101515-08-6, 7'-Deaza-2'-deoxyguanosine-5'-triphosphate
 RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
 (of nucleic acid analog substrate; nucleic acid detection and identification using site-specific cleavage, especially for anal. of human disease-related mutant gene or microbial pathogen nucleic acid anal.)
 RN 101515-08-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonoxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s L10 and (interferon or toll-like
 UNMATCHED LEFT PARENTHESIS 'AND (INTERFERON'
 The number of right parentheses in a query must be equal to the number of left parentheses.

=> s L10 and (interferon or (toll-like))
 75756 INTERFERON
 8174 TOLL
 779783 LIKE

7160 TOLL-LIKE
(TOLL(W)LIKE)

L11 0 L10 AND (INTERFERON OR (TOLL-LIKE))

=> d L10 1-8 ti

L10 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)

L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Immunomodulatory compositions, formulations, and methods for use thereof

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Method for controlling the fidelity and the process-execution of reverse transcriptase by incorporating and polymerizing nucleotide analogues acceptable as substrates for reverse transcription without blocking elongation

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Methods using nucleotide analogs for modulation and inhibition of telomerase for treatment of cancer

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Methods and compositions using nucleotide and nucleoside analogs for modulation and inhibition of telomerase, analog preparation, and use for cancer treatment

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Nucleic acid detection and identification using site-specific cleavage, especially for analysis of human disease-related mutant gene or microbial pathogen nucleic acid analysis

=> s l8

L12 183 L8

=> s L12 and (interferon or (toll-like))

75756 INTERFERON

8174 TOLL

779783 LIKE

7160 TOLL-LIKE

(TOLL(W)LIKE)

L13 0 L12 AND (INTERFERON OR (TOLL-LIKE))

=> s L12 and (oligonucleotide or polynucleotide)

0 OLIGONUCLEOTIE

13387 POLYNUCLEOTIDE

L14 10 L12 AND (OLIGONUCLEOTIE OR POLYNUCLEOTIDE)

=> s L12 and (oligonucleotide or polynucleotide)

55790 OLIGONUCLEOTIDE

13387 POLYNUCLEOTIDE

L15 49 L12 AND (OLIGONUCLEOTIDE OR POLYNUCLEOTIDE)

=> s l15 and (cancer or tumor or neoplas?)

308734 CANCER

401000 TUMOR

484696 NEOPLAS?

L16 4 L15 AND (CANCER OR TUMOR OR NEOPLAS?)

=> d l16 1-4 ti abs bib

L16 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Amplification of whole genome and whole transcriptome libraries generated by self-inert, degenerate primers and uses thereof

AB The invention comprises a variety of methods and compns. for whole genome amplification and whole transcriptome amplification. In a particular aspect of the present invention, there is a method of amplifying a genome comprising a library generation step followed by a library amplification step. In specific embodiments, the library generating step utilizes specific primer mixts. and a DNA polymerase, wherein the specific primer mixts. are designed to eliminate ability to self-hybridize and/or hybridize to other primers within a mixture but efficiently and frequently prime nucleic acid templates. Methods of the invention are claimed for use in microarrays, anal. of nucleic acids from single cells, chromatin, uncultured microorganisms, and extinct species, for cancer diagnosis and monitoring, blood anal., urine anal., and for nucleic acids samples from other body fluids and tissues. Pyrimidine primers comprising a constant 18-base sequence, followed by 10 random pyrimidines and 3 random bases or less at the 3' end did not self-prime when tested with a model template oligonucleotide having 10 random purine bases at its 3' terminus. A degenerate primer containing guanine and thymidine (K), primer K(N)2, supported the most uniform whole genome amplification as determined by quantitation with a panel of human genomic STS markers. Whole genome libraries prepared using methods of the invention can be converted for sequence-specific amplification by PCR re-amplification using universal primers with 5' C10 termini. Targeted amplification was evaluated in a multiplex format using 45 specific primers that were adjacent to STS sites and universal C10 primer.

AN 2004:780857 CAPLUS <<LOGINID::20070314>>

DN 141:290014

TI Amplification of whole genome and whole transcriptome libraries generated by self-inert, degenerate primers and uses thereof

IN Kamberov, Emmanuel; Sun, Tong; Bruening, Eric; Pinter, Jon; Sleptsova, Irina; Kurihara, Takao; Makarov, Vladimir L.

PA Rubicon Genomics, Inc., USA

SO PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004081225	A2	20040923	WO 2004-US6983	20040308
	WO 2004081225	A3	20041125		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004209298	A1	20041021	US 2004-795667	20040308
	EP 1604040	A2	20051214	EP 2004-718499	20040308

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

JP 2006519621 T 20060831 JP 2006-509236 20040308
US 2007054311 A1 20070308 US 2006-593625 20061106
PRAI US 2003-453060P P 20030307
US 2004-795667 A3 20040308
WO 2004-US6983 W 20040308

L16 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI In vitro DNA immortalization and whole genome amplification using
libraries generated from randomly fragmented DNA

AB The present invention regards a variety of methods and compns. for whole
genome amplification. In a particular aspect of the present invention,
there is a method of amplifying a genome in a non-biased manner utilizing
adaptor-attached randomly generated fragments following modification of
the DNA ends prior to the adaptor attachment. Two distinct methods of
library preparation are presented based on on 3 methods of DNA fragmentation.
When DNA is randomly fragmented in such a way as to result in the production
of double-stranded DNA fragments, adaptors comprising known sequence are
attached to a plurality of DNA fragments regardless of size and these
fragments amplified without bias. When DNA is randomly fragmented in such
a way as to result in the production of single-stranded DNA fragments, the
single-stranded fragments are converted into DNA fragments that are
double-stranded at both ends. This conversion to double-stranded ends
allows the efficient attachment of adaptors to a plurality of DNA
fragments regardless of size. In an addnl. aspect of the present
invention, there are methods and compns. for whole genome amplification
regarding a one-step endonuclease cleavage and linker ligation reaction.
The invention provides high-throughput library construction in the absence
of multiple steps and the requirement for having to purify DNA between
each step. The need for high throughput library construction is acute for
large-scale genome sequencing projects and for amplifying thousands of
clin. samples of limited quantity by whole genome amplification.

AN 2004:780819 CAPLUS <<LOGINID::20070314>>

DN 141:272594

TI In vitro DNA immortalization and whole genome amplification using
libraries generated from randomly fragmented DNA

IN Pinter, Jon; Kurihara, Takao; Sleptsova, Irina; Bruening, Eric; Ziebler,
William; Makarov, Vladimir L.

PA Rubicon Genomics, Inc., USA

SO PCT Int. Appl., 205 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004081183	A2	20040923	WO 2004-US6982	20040308
	WO 2004081183	A3	20050512		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG

US 2004209299 A1 20041021 US 2004-797333 20040308

EP 1606417 A2 20051221 EP 2004-718507 20040308

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

PRAI US 2003-453071P P 20030307
WO 2004-US6982 W 20040308

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Detection of nucleic acid sequences by isothermal RNA polymerase-dependent primer extension using reporter group-labeled nucleotides

AB A method of detecting nucleic acid sequences by measuring primer-dependent incorporation of a nucleotide analog s containing a reporter group into the primer extension product is described. The nucleotide analogs are preferably 5-S-substituted pyrimidines or 8-S-substituted purines. Such analogs may be incorporated into nucleic acids. In one embodiment, the process generates multiple amplification products from the primer and target. The methods generally comprise using a nucleoside, a mononucleotide, an oligonucleotide, or a polynucleotide, or analog thereof, to initiate synthesis of an oligonucleotide product that is substantially complementary to a target site on the defined polynucleotide sequence; optionally using nucleotides or nucleotide analogs as oligonucleotide chain elongators or chain terminators to terminate the polymerization reaction; and detecting multiple oligonucleotide products that have been synthesized by the polymerase.

AN 2004:220076 CAPLUS <<LOGINID::20070314>>

DN 140:248188

TI Detection of nucleic acid sequences by isothermal RNA polymerase-dependent primer extension using reporter group-labeled nucleotides

IN Hanna, Michelle M.

PA USA

SO U.S. Pat. Appl. Publ., 104 pp., Cont.-in-part of Appl. No. PCT/US02/34419. CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004054162	A1	20040318	US 2003-425037	20030429
	US 2003099950	A1	20030529	US 2001-984664	20011030
	US 7045319	B2	20060516		
	WO 2003038042	A2	20030508	WO 2002-US34419	20021029
	WO 2003038042	A3	20040325		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU	2004235368	A1	20041111	AU 2004-235368	20040429
CA	2523442	A1	20041111	CA 2004-2523442	20040429
WO	2004096997	A2	20041111	WO 2004-US13031	20040429
WO	2004096997	A3	20050915		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

EP 1622923	A2	20060208	EP 2004-750780	20040429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006525022	T	20061109	JP 2006-513381	20040429
US 2006204964	A1	20060914	US 2005-551775	20051003
IN 2005KN02167	A	20060901	IN 2005-KN2167	20051102
PRAI US 2001-984664	A2	20011030		
WO 2002-US34419	A2	20021029		
US 2003-425037	A	20030429		
WO 2004-US13031	W	20040429		

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Immunomodulatory compositions, formulations, and methods for use thereof

AB The invention provides new compns. and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6mer immunomodulatory oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also provided are immunomodulatory compns. comprising a 3-6mer IMO encapsulated in an MC.

AN 2003:133429 CAPLUS <<LOGINID::20070314>>

DN 138:210275

TI Immunomodulatory compositions, formulations, and methods for use thereof

IN Fearon, Karen L.; Dina, Dino

PA Dynavax Technologies Corporation, USA

SO PCT Int. Appl., 79 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003014316	A2	20030220	WO 2002-US25123	20020807
	WO 2003014316	A3	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2456328	A1	20030220	CA 2002-2456328	20020807
	US 2003133988	A1	20030717	US 2002-214799	20020807
	EP 1420829	A2	20040526	EP 2002-761284	20020807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005527465	T	20050915	JP 2003-519446	20020807
PRAI	US 2001-310743P	P	20010807		
	US 2001-335263P	P	20011025		
	WO 2002-US25123	W	20020807		
OS	MARPAT 138:210275				

(FILE 'HOME' ENTERED AT 08:49:45 ON 14 MAR 2007)

FILE 'REGISTRY' ENTERED AT 08:49:58 ON 14 MAR 2007

L1 STRUCTURE UPLOADED
L2 STRUCTURE UPLOADED
L3 50 S L2
L4 34165 S L3 SSS FULL
L5 0 S L1 SUB=L4 FULL
L6 STRUCTURE UPLOADED
L7 33945 S L6 SUB=L4 FULL
L8 220 S L4 NOT L7

FILE 'CAPLUS' ENTERED AT 08:53:37 ON 14 MAR 2007

L9 15 S L8/THU
L10 8 S L9 AND (INTERFERON OR (TOLL-LIKE) OR CANCER OR VIRUS OR VIRAL
L11 0 S L10 AND (INTERFERON OR (TOLL-LIKE))
L12 183 S L8
L13 0 S L12 AND (INTERFERON OR (TOLL-LIKE))
L14 10 S L12 AND (OLIGONUCLEOTIE OR POLYNUCLEOTIDE)
L15 49 S L12 AND (OLIGONUCLEOTIDE OR POLYNUCLEOTIDE)
L16 4 S L15 AND (CANCER OR TUMOR OR NEOPLAS?)

=> file registry
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.21	0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 08:49:58 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6
DICTIONARY FILE UPDATES: 13 MAR 2007 HIGHEST RN 926304-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH December 2, 2006



Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10824833nucnot.str



chain nodes :

7 8 20 21 22 23 24 25 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 9 10 11 14 15 16 17 18

chain bonds :

2-8 4-7 10-31 11-14 14-29 16-22 16-26 17-21 17-27 18-20 18-28 22-23

22-24

22-25 23-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 6-11 9-10 10-11 14-15 14-18 15-16 16-17

17-18

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 5-9 6-11 9-10 10-11 10-31 14-15 14-18

15-16 16-17 17-18 17-21 18-20 22-23 23-30

exact bonds :

11-14 14-29 16-22 16-26 17-27 18-28 22-24 22-25

G1:C,S,N

G2:C,N

G3:H,O

G4:H,Cl,Br,F,I,NO2



Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

L1 STRUCTURE UPLOADED

=>

Uploading C:\Program Files\Stnexp\Queries\10824833nuc2.str



chain nodes :

7 8 20 21 22 23 24 25 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 9 10 11 14 15 16 17 18

chain bonds :

2-8 4-7 10-31 11-14 14-29 16-22 16-26 17-21 17-27 18-20 18-28 22-23

22-24

22-25 23-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 6-11 9-10 10-11 14-15 14-18 15-16 16-17

17-18

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 5-9 6-11 9-10 10-11 10-31 11-14 14-15

14-18 14-29 15-16 16-17 16-22 16-26 17-18 17-21 17-27 18-20 18-28 22-23

22-24 22-25

23-30

G1:C,S,N

G2:C,N

G3:H,O

G4:H,Cl,Br,F,I,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

L2 STRUCTURE UPLOADED

=> d l2

L2 HAS NO ANSWERS

L2 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l2

SAMPLE SEARCH INITIATED 08:50:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1985 TO ITERATE

100.0% PROCESSED 1985 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 37028 TO 42372

PROJECTED ANSWERS: 31103 TO 36017

L3 50 SEA SSS SAM L2

=> s l3 sss full

FULL SEARCH INITIATED 08:50:56 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 40417 TO ITERATE

100.0% PROCESSED 40417 ITERATIONS

34165 ANSWERS

SEARCH TIME: 00.00.01

L4 34165 SEA SSS FUL L2

=> s L1 sub=L4

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 08:51:18 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 41 TO ITERATE

100.0% PROCESSED 41 ITERATIONS

0 ANSWERS


SEARCH TIME: 00.00.01

L5 0 SEA SUB=L4 SSS FUL L1


=> d 14 scan

L4 34165 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN INDEX NAME NOT YET ASSIGNED
MF C52 H57 B F2 N9 O18 P3 S
CI CCS, COM


PAGE 1-A



PAGE 1-B




PAGE 1-C



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):3


L4 34165 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C52 H57 B F2 N9 O18 P3 S . 2 H
 CI CCS

PAGE 1-A



● 2 H⁺

PAGE 1-B



—NH₂


—CH=CH₂

L4 34165 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C78 H99 N30 O46 P7 . 1/2 C16 H12 N2 O4



CM 1

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B




PAGE 2-A








CM 2




L4 34165 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN INDEX NAME NOT YET ASSIGNED
 MF C57 H70 N21 O42 P5


Absolute stereochemistry.



PAGE 2-A





PAGE 2-B



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=>

Uploading C:\Program Files\Stnexp\Queries\10823844nucnot2.str



chain nodes :

7 8 20 21 22 23 24 25 26 27 28 29 30 31

ring nodes :

1 2 3 4 5 6 9 10 11 14 15 16 17 18

chain bonds :

2-8 4-7 10-31 11-14 14-29 16-22 16-26 17-21 17-27 18-20 18-28 22-23

22-24

22-25 23-30

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6 5-9 6-11 9-10 10-11 14-15 14-18 15-16 16-17

17-18

exact/norm bonds :

1-2 1-6 2-3 2-8 3-4 4-5 4-7 5-6 5-9 6-11 9-10 10-11 10-31 11-14 14-15

14-18 15-16 16-17 17-18 17-21 18-20 22-23 23-30

exact bonds :

14-29 16-22 16-26 17-27 18-28 22-24 22-25

G1:C,S,N

G2:C,N

G3:H,O

G4:H,Cl,Br,F,I,NO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 20:CLASS 21:CLASS 22:CLASS
23:CLASS 24:CLASS
25:CLASS 26:CLASS 27:CLASS 28:CLASS 29:CLASS 30:CLASS 31:CLASS

L6 STRUCTURE UPLOADED

=> s L6 sub=L4

ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):full

FULL SUBSET SEARCH INITIATED 08:52:45 FILE 'REGISTRY'

FULL SUBSET SCREEN SEARCH COMPLETED - 33951 TO ITERATE

100.0% PROCESSED 33951 ITERATIONS

33945 ANSWERS

SEARCH TIME: 00.00.01

L7 33945 SEA SUB=L4 SSS FUL L6

=> s l4 not L7

L8 220 L4 NOT L7


=> d l8 scan

L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN

IN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-
[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-
ribofuranosyl]-1,7-dihydro- (9CI)

MF C11 H16 F N4 O13 P3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):4


L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN



IN 7-Deazaguanosine, 2'-deoxycytidyl-(3'→5')-2'-deoxy-7-deazaguanyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxy-7-deazaguanyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxy-(9CI)

MF C60 H76 N21 O34 P5

Absolute stereochemistry.

PAGE 1-A











PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN 7-Deazaguanosine, 2'-deoxycytidylyl-(3'→5')-2'-deoxy-7-
 deazaguanilyl-(3'→5')-2'-deoxyadenilyl-(3'→5')-2'-
 deoxyadenilyl-(3'→5')-2'-deoxycytidylyl-(3'→5')-thymidylyl-
 (3'→5')-2'-deoxy- (9CI)
 MF C70 H88 N26 O39 P6

Absolute stereochemistry.






PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT


L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Borate(4-), [N-[3-[2-amino-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphiny
 l]oxy]phosphinyl]-β-D-ribofuranosyl]-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-
 d]pyrimidin-5-yl]-2-propynyl]-5-[[5-(1H-pyrrol-2-yl)-2H-pyrrol-2-ylidene-
 κN]methyl]-1H-pyrrole-2-propanamido(5-)-κN1]difluoro-,
 tetrahydrogen, (T-4)- (9CI)
 MF C30 H28 B F2 N8 O15 P3 . 4 H
 CI CCS

PAGE 1-A




● 4 H⁺

PAGE 1-B



L8 220 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
 IN Acetamide, N-[3-[2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy
)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo-1H-pyrrolo[2,3-
 d]pyrimidin-5-yl]-2-propynyl]-2,2,2-trifluoro- (9CI)
 MF C16 H19 F3 N5 O15 P3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):file caplus.
'FILE CAPLUS' IS NOT VALID HERE

To display more answers, enter the number of answers you would like to see. To end the display, enter "NONE", "N", "0", or "END".
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
255.65	255.86

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:53:37 ON 14 MAR 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 14 Mar 2007 VOL 146 ISS 12
FILE LAST UPDATED: 13 Mar 2007 (20070313/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l8/thu

183 L8
866657 THU/RL
L9 15 L8/THU
(L8 (L) THU/RL)

=> s l9 and (interferon or (toll-like) or cancer or virus or viral)
75756 INTERFERON

8174 TOLL
 779783 LIKE
 7160 TOLL-LIKE
 (TOLL(W) LIKE)
 308734 CANCER
 357456 VIRUS
 167790 VIRAL

L10 8 L9 AND (INTERFERON OR (TOLL-LIKE) OR CANCER OR VIRUS OR VIRAL)

=> d l10 1-8 hitstr

L10 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 98259-20-2 101515-08-6 181356-39-8

213623-48-4 244109-12-4 377048-29-8

444019-41-4 444019-42-5 444019-43-6

444019-46-9 444019-47-0 444019-48-1

444019-50-5 444019-52-7 444019-53-8

444019-79-8 444021-39-0 847649-04-1

847649-60-9 847650-14-0 847650-15-1

847650-28-6 847650-29-7


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(comps. and methods for treatment of severe acute respiratory syndrome)

RN 98259-20-2 CAPLUS


CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)



RN 101515-08-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 181356-39-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-

[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 213623-48-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-erythro-pentofuranosyl]-5-ethyl-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 244109-12-4 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-erythro-pentofuranosyl]-1,7-dihydro-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 377048-29-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-erythro-

pentofuranosyl]-1,7-dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-41-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-42-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444019-43-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-ethyl-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-

ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-46-9 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-47-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-48-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-50-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]]-β-D-arabinofuranosyl]-5-methyl- (9CI) (CA INDEX NAME).


Absolute stereochemistry.



RN 444019-52-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]]-β-D-erythro-pentofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-53-8 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[5-O-[[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]]-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-79-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy([hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl]-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-39-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy([hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl]-β-D-arabinofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847649-04-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy([hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl]-α-D-arabinofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847649-60-9 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-beta-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-14-0 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-D-arabinofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-15-1 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-alpha-D-arabinofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-28-6 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-3,5-dihydro-7-[5-O-
[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-
β-D-ribofuranosyl]-3-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 847650-29-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[[bis[2-
[(trifluoroacetyl)thio]ethoxy]phosphinyl]-2-O-methyl-β-D-
ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 444019-45-8 444021-39-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)


(a 7-deaza-adenosine analog is a potent and selective inhibitor of
hepatitis C virus replication with excellent pharmacokinetic

properties)

RN 444019-45-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-39-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN



IT 499212-95-2




RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (immunomodulatory oligonucleotide compns. for use with microcarriers)

RN 499212-95-2 CAPLUS

CN Thymidine, P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thio-7-deazaguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

IT 101515-08-6P 181356-39-8P 444019-15-2P

444019-41-4P 444019-42-5P 444019-43-6P

444019-45-8P 444019-46-9P 444019-47-0P

444019-48-1P 444019-49-2P 444019-50-5P

444019-51-6P 444019-52-7P 444019-53-8P

444019-79-8P 444020-98-8P 444021-00-5P

444021-01-6P 444021-06-1P 444021-07-2P

444021-10-7P 444021-11-8P 444021-12-9P

444021-36-7P 444021-37-8P 444021-39-0P

444021-40-3P 444021-41-4P 444021-42-5P

444021-69-6P 444021-77-6P 444021-80-1P

444021-81-2P 444021-84-5P 444021-85-6P

RL: IMF (Industrial manufacture); PAC (Pharmacological activity); SPN

(Synthetic preparation); THU (Therapeutic use); BIOL (Biological


study); PREP (Preparation); USES (Uses)

(preparation of nucleoside derivs. as inhibitors of RNA-dependent human RNA viral polymerase)

RN 101515-08-6 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 181356-39-8 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444019-15-2 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[5-O-[bis[2-[(2,2-dimethyl-1-oxopropyl)thio]ethoxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444019-41-4 CAPLUS
 CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-42-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-43-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-ethyl-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-45-8 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444019-46-9 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444019-47-0 CAPLUS
 CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444019-48-1 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl-β-D-ribofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-49-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-1,7-dihydro-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-50-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-51-6 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444019-52-7 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-5-O-

[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-erythro-pentofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-53-8 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-2-O-methyl- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444019-79-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]- β -D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444020-98-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carboxamide, 2-amino-4,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-

trioxa-1-phosphaoct-1-yl]- β -D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-00-5 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]- β -D-ribofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-01-6 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-5-ethyl-1,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]- β -D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-06-1 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[2-O-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-07-2 CAPLUS

CN 4H-Pyrrolo[3,2-d]pyrimidin-4-one, 2-amino-1,5-dihydro-7-[2-O-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-10-7 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-[5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444021-11-8 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[2-O-


methyl-5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]-4-oxo- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 444021-12-9 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-[2-O-methyl-5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444021-36-7 CAPLUS
CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-37-8 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]-1,7-dihydro- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 444021-39-0 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-40-3 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy) carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-41-4 CAPLUS

CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-4,7-dihydro-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-42-5 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-methyl-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-arabinofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 444021-69-6 CAPLUS


CN 1H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-amino-7-[2-deoxy-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-erythro-pentofuranosyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444021-77-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-2-fluoro-5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444021-80-1 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-ribofuranosyl]-5-iodo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444021-81-2 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-5-iodo-7-[5-O-[7-methyl-1-[[[(1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 444021-84-5 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-1,7-dihydro-7-[5-O-[7-methyl-1-
 [[[1-methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-
 phosphaoct-1-yl]-β-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 444021-85-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[7-methyl-1-[[[1-
 methylethoxy)carbonyl]oxy]methoxy]-1-oxido-5-oxo-2,4,6-trioxa-1-phosphaoct-
 1-yl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 101515-08-6
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process);
 USES (Uses)
 (controlling the fidelity and the process-execution of reverse transcriptase by incorporating and polymerizing nucleotide analogs acceptable as substrates for reverse transcription without blocking elongation)

RN 101515-08-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN


IT 252722-18-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide analogs for modulation and inhibition of telomerase for treatment of cancer)

RN 252722-18-2 CAPLUS

CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-3,7-dihydro-3-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 101515-08-6

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(nucleotide analogs for modulation and inhibition of telomerase for treatment of cancer)

RN 101515-08-6 CAPLUS


CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 101515-08-6, 7-Deaza-2'-deoxyguanosine 5'-triphosphate
 104904-92-9 187478-95-1
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nucleotide and nucleoside analogs for modulation and inhibition of telomerase, analog preparation, and use for cancer treatment)
 RN 101515-08-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 104904-92-9 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy(phosphonooxy)phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187478-95-1 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[hydroxy(phosphonomethyl)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN
 IT 101515-08-6, 7'-Deaza-2'-deoxyguanosine-5'-triphosphate
 RL: ANT (Analyte); BPR (Biological process); BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); PROC (Process); USES (Uses)
 (of nucleic acid analog substrate; nucleic acid detection and identification using site-specific cleavage, especially for anal. of human disease-related mutant gene or microbial pathogen nucleic acid anal.)
 RN 101515-08-6 CAPLUS
 CN 4H-Pyrrolo[2,3-d]pyrimidin-4-one, 2-amino-7-[2-deoxy-5-O-[hydroxy[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-β-D-erythro-pentofuranosyl]-1,7-dihydro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> s L10 and (interferon or toll-like
 UNMATCHED LEFT PARENTHESIS 'AND (INTERFERON'
 The number of right parentheses in a query must be equal to the number of left parentheses.

=> s L10 and (interferon or (toll-like))
 75756 INTERFERON
 8174 TOLL
 779783 LIKE

7160 TOLL-LIKE
(TOLL(W)LIKE)

L11 0 L10 AND (INTERFERON OR (TOLL-LIKE))

=> d L10 1-8 ti

L10 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)

L10 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties

L10 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Immunomodulatory compositions, formulations, and methods for use thereof

L10 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Preparation of nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase

L10 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Method for controlling the fidelity and the process-execution of reverse transcriptase by incorporating and polymerizing nucleotide analogues acceptable as substrates for reverse transcription without blocking elongation

L10 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Methods using nucleotide analogs for modulation and inhibition of telomerase for treatment of cancer

L10 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Methods and compositions using nucleotide and nucleoside analogs for modulation and inhibition of telomerase, analog preparation, and use for cancer treatment

L10 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2007 ACS on STN

TI Nucleic acid detection and identification using site-specific cleavage, especially for analysis of human disease-related mutant gene or microbial pathogen nucleic acid analysis

=> s l8

L12 183 L8

=> s L12 and (interferon or (toll-like))

75756 INTERFERON

8174 TOLL

779783 LIKE

7160 TOLL-LIKE

(TOLL(W)LIKE)

L13 0 L12 AND (INTERFERON OR (TOLL-LIKE))

=> s L12 and (oligonucleotide or polynucleotide)

0 OLIGONUCLEOTIDE

13387 POLYNUCLEOTIDE

L14 10 L12 AND (OLIGONUCLEOTIDE OR POLYNUCLEOTIDE)

=> s L12 and (oligonucleotide or polynucleotide)

55790 OLIGONUCLEOTIDE

13387 POLYNUCLEOTIDE

L15 49 L12 AND (OLIGONUCLEOTIDE OR POLYNUCLEOTIDE)

=> s l15 and (cancer or tumor or neoplas?)
 308734 CANCER
 401000 TUMOR
 484696 NEOPLAS?
 L16 4 L15 AND (CANCER OR TUMOR OR NEOPLAS?)

=> d l16 1-4 ti abs bib

L16 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Amplification of whole genome and whole transcriptome libraries generated by self-inert, degenerate primers and uses thereof
 AB The invention comprises a variety of methods and compns. for whole genome amplification and whole transcriptome amplification. In a particular aspect of the present invention, there is a method of amplifying a genome comprising a library generation step followed by a library amplification step. In specific embodiments, the library generating step utilizes specific primer mixts. and a DNA polymerase, wherein the specific primer mixts. are designed to eliminate ability to self-hybridize and/or hybridize to other primers within a mixture but efficiently and frequently prime nucleic acid templates. Methods of the invention are claimed for use in microarrays, anal. of nucleic acids from single cells, chromatin, uncultured microorganisms, and extinct species, for cancer diagnosis and monitoring, blood anal., urine anal., and for nucleic acids samples from other body fluids and tissues. Pyrimidine primers comprising a constant 18-base sequence, followed by 10 random pyrimidines and 3 random bases or less at the 3' end did not self-prime when tested with a model template oligonucleotide having 10 random purine bases at its 3' terminus. A degenerate primer containing guanine and thymidine (K), primer K(N)2, supported the most uniform whole genome amplification as determined by quantitation with a panel of human genomic STS markers. Whole genome libraries prepared using methods of the invention can be converted for sequence-specific amplification by PCR re-amplification using universal primers with 5' C10 termini. Targeted amplification was evaluated in a multiplex format using 45 specific primers that were adjacent to STS sites and universal C10 primer.

AN 2004:780857 CAPLUS <<LOGINID::20070314>>

DN 141:290014

TI Amplification of whole genome and whole transcriptome libraries generated by self-inert, degenerate primers and uses thereof

IN Kamberov, Emmanuel; Sun, Tong; Bruening, Eric; Pinter, Jon; Sleptsova, Irina; Kurihara, Takao; Makarov, Vladimir L.

PA Rubicon Genomics, Inc., USA

SO PCT Int. Appl., 208 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004081225	A2	20040923	WO 2004-US6983	20040308
	WO 2004081225	A3	20041125		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW,			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004209298	A1	20041021	US 2004-795667	20040308
	EP 1604040	A2	20051214	EP 2004-718499	20040308

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
 JP 2006519621 T 20060831 JP 2006-509236 20040308
 US 2007054311 A1 20070308 US 2006-593625 20061106
 PRAI US 2003-453060P P 20030307
 US 2004-795667 A3 20040308
 WO 2004-US6983 W 20040308

L16 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI In vitro DNA immortalization and whole genome amplification using
 libraries generated from randomly fragmented DNA

AB The present invention regards a variety of methods and compns. for whole
 genome amplification. In a particular aspect of the present invention,
 there is a method of amplifying a genome in a non-biased manner utilizing
 adaptor-attached randomly generated fragments following modification of
 the DNA ends prior to the adaptor attachment. Two distinct methods of
 library preparation are presented based on on 3 methods of DNA fragmentation.
 When DNA is randomly fragmented in such a way as to result in the production
 of double-stranded DNA fragments, adaptors comprising known sequence are
 attached to a plurality of DNA fragments regardless of size and these
 fragments amplified without bias. When DNA is randomly fragmented in such
 a way as to result in the production of single-stranded DNA fragments, the
 single-stranded fragments are converted into DNA fragments that are
 double-stranded at both ends. This conversion to double-stranded ends
 allows the efficient attachment of adaptors to a plurality of DNA
 fragments regardless of size. In an addnl. aspect of the present
 invention, there are methods and compns. for whole genome amplification
 regarding a one-step endonuclease cleavage and linker ligation reaction.
 The invention provides high-throughput library construction in the absence
 of multiple steps and the requirement for having to purify DNA between
 each step. The need for high throughput library construction is acute for
 large-scale genome sequencing projects and for amplifying thousands of
 clin. samples of limited quantity by whole genome amplification.

AN 2004:780819 CAPLUS <<LOGINID::20070314>>

DN 141:272594

TI In vitro DNA immortalization and whole genome amplification using
 libraries generated from randomly fragmented DNA

IN Pinter, Jon; Kurihara, Takao; Sleptsova, Irina; Bruening, Eric; Ziehler,
 William; Makarov, Vladimir L.

PA Rubicon Genomics, Inc., USA

SO PCT Int. Appl., 205 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004081183	A2	20040923	WO 2004-US6982	20040308
	WO 2004081183	A3	20050512		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2004209299	A1	20041021	US 2004-797333	20040308
	EP 1606417	A2	20051221	EP 2004-718507	20040308
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK			

PRAI US 2003-453071P P 20030307
WO 2004-US6982 W 20040308

L16 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN

TI Detection of nucleic acid sequences by isothermal RNA polymerase-dependent primer extension using reporter group-labeled nucleotides

AB A method of detecting nucleic acid sequences by measuring primer-dependent incorporation of a nucleotide analog s containing a reporter group into the primer extension product is described. The nucleotide analogs are preferably 5-S-substituted pyrimidines or 8-S-substituted purines. Such analogs may be incorporated into nucleic acids. In one embodiment, the process generates multiple amplification products from the primer and target. The methods generally comprise using a nucleoside, a mononucleotide, an oligonucleotide, or a polynucleotide, or analog thereof, to initiate synthesis of an oligonucleotide product that is substantially complementary to a target site on the defined polynucleotide sequence; optionally using nucleotides or nucleotide analogs as oligonucleotide chain elongators or chain terminators to terminate the polymerization reaction; and detecting multiple oligonucleotide products that have been synthesized by the polymerase.

AN 2004:220076 CAPLUS <<LOGINID::20070314>>

DN 140:248188

TI Detection of nucleic acid sequences by isothermal RNA polymerase-dependent primer extension using reporter group-labeled nucleotides

IN Hanna, Michelle M.

PA USA

SO U.S. Pat. Appl. Publ., 104 pp., Cont.-in-part of Appl. No. PCT/US02/34419.
CODEN: USXXCO

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2004054162	A1	20040318	US 2003-425037	20030429
	US 2003099950	A1	20030529	US 2001-984664	20011030
	US 7045319	B2	20060516		
	WO 2003038042	A2	20030508	WO 2002-US34419	20021029
	WO 2003038042	A3	20040325		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU	2004235368	A1	20041111	AU 2004-235368	20040429
CA	2523442	A1	20041111	CA 2004-2523442	20040429
WO	2004096997	A2	20041111	WO 2004-US13031	20040429
WO	2004096997	A3	20050915		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

EP 1622923	A2	20060208	EP 2004-750780	20040429
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006525022	T	20061109	JP 2006-513381	20040429
US 2006204964	A1	20060914	US 2005-551775	20051003
IN 2005KN02167	A	20060901	IN 2005-KN2167	20051102
PRAI US 2001-984664	A2	20011030		
WO 2002-US34419	A2	20021029		
US 2003-425037	A	20030429		
WO 2004-US13031	W	20040429		

L16 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2007 ACS on STN
 TI Immunomodulatory compositions, formulations, and methods for use thereof
 AB The invention provides new compns. and methods for immunomodulation of individuals. Immunomodulation is accomplished by administration of immunomodulatory polynucleotide/microcarrier (IMO/MC) complexes comprising 3-6mer immunomodulatory oligonucleotides. The IMO/MC complexes may be covalently or non-covalently bound. Also provided are immunomodulatory compns. comprising a 3-6mer IMO encapsulated in an MC.
 AN 2003:133429 CAPLUS <<LOGINID::20070314>>
 DN 138:210275
 TI Immunomodulatory compositions, formulations, and methods for use thereof
 IN Fearon, Karen L.; Dina, Dino
 PA Dynavax Technologies Corporation, USA
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003014316	A2	20030220	WO 2002-US25123	20020807
	WO 2003014316	A3	20040311		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2456328	A1	20030220	CA 2002-2456328	20020807
	US 2003133988	A1	20030717	US 2002-214799	20020807
	EP 1420829	A2	20040526	EP 2002-761284	20020807
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005527465	T	20050915	JP 2003-519446	20020807
PRAI	US 2001-310743P	P	20010807		
	US 2001-335263P	P	20011025		
	WO 2002-US25123	W	20020807		
OS	MARPAT 138:210275				